NCT06029816View on ClinicalTrials.gov

Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions

NSCLC

Interventions

DRUG

Neratinib tablets

Neratinib tablets

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Convalife (Shanghai) Co., Ltd.

INDUSTRY